HOUSTON, JUNE 11, 2026 ― A brand new therapy platform developed by researchers at The College of Texas MD Anderson Most cancers Middle was capable of ship messenger RNA (mRNA) of the full-length DMD gene into preclinical fashions of Duchenne muscular dystrophy, efficiently restoring the manufacturing of an necessary muscle protein, dystrophin, and dramatically enhancing muscle energy, endurance and performance in vivo.
The research, printed immediately in Nature Biomedical Engineering , was co-led by Betty Kim, M.D., Ph.D. , professor of Neurosurgery and core member of the James P. Allison Institute ™, and Wen Jiang, M.D., Ph.D. , affiliate professor of CNS Radiation Oncology .
The method makes use of engineered extracellular vesicles (EVs) — pure nanoscale supply particles — which supply distinct advantages over present viral-based gene therapies, together with diminished unwanted side effects and the power to switch your entire DMD gene. The researchers engineered the EVs with particular tags that immediately goal skeletal muscle tissue after being injected into the bloodstream.
“Our new platform overcomes the constraints of present viral-based gene therapies, permitting for the supply of full-length mRNA, restoring wild-type translation of dystrophin and considerably enhancing muscle perform,” Kim mentioned. “We’re extremely inspired by these outcomes, which offer a blueprint for mRNA-loaded EVs as a next-generation therapeutic technique.”
What’s Duchenne muscular dystrophy and what are the constraints of present gene therapies?
Duchenne muscular dystrophy is a extreme genetic dysfunction that causes muscle weak point and degeneration. It’s attributable to mutations within the DMD gene that forestall the physique from producing dystrophin, which helps stabilize and shield muscle cells throughout contractions in wholesome people. With out dystrophin, the muscle tissue turn into simply broken, resulting in eventual irritation and cell dying.
Duchenne muscular dystrophy primarily impacts males, with signs corresponding to delayed strolling and waddling normally showing in early childhood. Because the illness progresses, it results in lack of strolling potential, scoliosis, coronary heart issues and eventual respiratory failure.
As a result of DMD is the longest recognized gene within the human genome, present viral-based gene therapies are unable to hold the complete size, which means they have to use shortened variations that deal with completely different signs. These limitations consequence within the lack of the gene’s full perform and include severe unwanted side effects, dose-limiting toxicities, immune reactions and even doable dying.
These unwanted side effects have resulted within the removing of at the least one Meals and Drug Administration-approved gene remedy from the market and are partly why researchers have been making an attempt to develop other ways of safely delivering the full-length DMD gene.
How is that this new remedy completely different?
mRNA know-how, which was acknowledged by the 2023 Nobel Prize in Physiology or Medication, holds nice potential in pathogenic infections in addition to ailments like most cancers. In truth, the researchers had beforehand used mRNA-loaded EVs to boost responses to immunotherapy in glioblastoma, suggesting the know-how’s potential use for most cancers remedy. Ongoing preclinical work continues to enhance manufacturing strategies and study the protection of EV-based mRNA remedy.
On this research, the researchers used their technique to load the full-length DMD mRNA into EVs that had been engineered to particularly goal and bind to skeletal muscle tissue. Injection of those mRNA-loaded EVs led to a rise in dystrophin protein expression in addition to improved muscle energy and performance in preclinical fashions, with no severe unwanted side effects.
Importantly, the therapy stayed on the right track within skeletal muscle tissue and didn’t set off any immune responses or toxicities generally seen with viral-based therapies, even after repeated dosage.
What are the broader implications for EV-mediated mRNA therapeutics?
Future research are wanted to find out the complete security of EV-mediated mRNA platforms for medical trials, together with whether or not they are often delivered to cardiac muscle tissue, as coronary heart situations are generally seen in superior illness. Nevertheless, based mostly on these outcomes, the authors level out this might be a promising technique past treating Duchenne muscular dystrophy, additionally doubtlessly serving as a broader “protein restoration” or mobile reprogramming platform.
“Provided that we at the moment are capable of substitute very giant proteins, this platform- and disease-agnostic method may doubtlessly open doorways far past uncommon genetic problems and conventional gene remedy purposes,” Kim mentioned. “It is doable this might in the end allow restoration of proteins misplaced not solely by inherited ailments but additionally from acquired or degenerative processes, together with most cancers, autoimmune problems, neurodegeneration, fibrosis and different power ailments.”
